Gilead to Make $60M Upfront Payment with a Total Deal Value of up to $848M

Foster City, CA & Holon, Israel, December 19, 2023 (Business Wire) -- Gilead Sciences, Inc. (Nasdaq: GILD) disclosed today a collaborative agreement with Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a leading cancer immunotherapy company in the clinical stage and an innovator in computational target discovery, based in Holon, Israel. The agreement entails the exclusive licensing of Compugen's promising pre-clinical antibody program targeting IL-18 binding protein, encompassing the potential first-in-class drug candidate, COM503.

Read full article here.